Literature DB >> 12562740

Impact of comorbid personality disorder on violence in psychosis: report from the UK700 trial.

Paul Moran1, Elizabeth Walsh, Peter Tyrer, Tom Burns, Francis Creed, Tom Fahy.   

Abstract

BACKGROUND: The impact of comorbid personality disorder on the occurrence of violence in psychosis has not been fully explored. AIMS: To examine the association between comorbid personality disorder and violence in community-dwelling patients with psychosis.
METHOD: A total of 670 patients with established psychotic illness were screened for comorbid personality disorder. Physical assault was measured from multiple data sources over the subsequent 2 years. Logistic regression was used to assess whether the presence of comorbid personality disorder predicted violence in the sample.
RESULTS: A total of 186 patients (28%) were rated as having a comorbid personality disorder. Patients with comorbid personality disorder were significantly more likely to behave violently over the 2-year period of the trial (adjusted odds ratio=1.71, 95% CI 1.05-2.79).
CONCLUSIONS: Comorbid personality disorder is independently associated with an increased risk of violent behaviour in psychosis.

Entities:  

Mesh:

Year:  2003        PMID: 12562740     DOI: 10.1192/bjp.182.2.129

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  15 in total

Review 1.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  Intensive case management for severe mental illness.

Authors:  Marina Dieterich; Claire B Irving; Hanna Bergman; Mariam A Khokhar; Bert Park; Max Marshall
Journal:  Cochrane Database Syst Rev       Date:  2017-01-06

3.  Personality disorder: a new global perspective.

Authors:  Peter Tyrer; Roger Mulder; Mike Crawford; Giles Newton-Howes; Erik Simonsen; David Ndetei; Nestor Koldobsky; Andrea Fossati; Joseph Mbatia; Barbara Barrett
Journal:  World Psychiatry       Date:  2010-02       Impact factor: 49.548

4.  Obsessive-compulsive disorder and personality disorder: evidence from the British National Survey of Psychiatric Morbidity 2000.

Authors:  Albina R Torres; Paul Moran; Paul Bebbington; Traolach Brugha; Dinesh Bhugra; Jeremy W Coid; Michael Farrell; Rachel Jenkins; Glyn Lewis; Howard Meltzer; Martin Prince
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2006-09-15       Impact factor: 4.328

5.  The impact of severe mental illness, co-morbid personality disorders and demographic factors on psychiatric bed use.

Authors:  Patrick Keown; Frank Holloway; Elizabeth Kuipers
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2005-01       Impact factor: 4.328

Review 6.  Psychotic disorders and repeat offending: systematic review and meta-analysis.

Authors:  Seena Fazel; Rongqin Yu
Journal:  Schizophr Bull       Date:  2009-12-03       Impact factor: 9.306

7.  Controversies surrounding classification of personality disorder.

Authors:  Youl-Ri Kim; Peter Tyrer
Journal:  Psychiatry Investig       Date:  2010-02-08       Impact factor: 2.505

8.  Criminal behavior among persons with schizophrenia in rural China.

Authors:  Mao-Sheng Ran; Peng-Yu Chen; Zhi-Gang Liao; Cecilia Lai-Wan Chan; Eric Yu-Hai Chen; Cui-Ping Tang; Wen-Jun Mao; J Steven Lamberti; Yeates Conwell
Journal:  Schizophr Res       Date:  2010-01-13       Impact factor: 4.939

9.  Program planning and staff competencies for forensic assertive community treatment: ACT-eligible versus FACT-eligible consumers.

Authors:  Gary S Cuddeback; Joseph P Morrissey
Journal:  J Am Psychiatr Nurses Assoc       Date:  2011 Jan-Feb       Impact factor: 2.385

10.  The impact of co-morbid personality disorder on use of psychiatric services and involuntary hospitalization in people with severe mental illness.

Authors:  Marcella Lei-Yee Fok; Robert Stewart; Richard D Hayes; Paul Moran
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2014-04-09       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.